Zusammenfassung
Urologika werden zur Behandlung von Miktionsstörungen im weitesten Sinne angewandt, denen Erkrankungen der Prostata und der Blase sowie verschiedene andere urologische Störungen zugrunde liegen können. Nach Indikationsgebieten differenziert, wurden vor allem Alpha1- Rezeptorenblocker und urologische Spasmolytika verordnet (Abbildung 43.1).
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
Similar content being viewed by others
Literatur
Alhasso AA, McKinlay J, Patrick K, Stewart L. Anticholinergic drugs versus non-drug active therapies for overactive bladder syndrome in adults. Cochrane Database Syst Rev. 2006; 4: CD003193.
Blake-James BT, Rashidian A, Ikeda Y, Emberton M (2007): The role of anticholinergics in men with lower urinary tract symptoms suggestive of benign prostatic hyperplasia: a systematic review and meta-analysis. BJU Int 99: 85–96.
Boyle P, Gould AL, Roehrborn CG (1996): Prostate volume predicts outcome of treatment of benign prostatic hyperplasia with finasteride: meta-analysis of randomized clinical trials. Urology 48: 398–405.
Chapple CR (1996): Selective a1-adrenoceptor antagonists in benign prostatic hyperplasia: rationale and clinical experience. Eur Urol 29: 129–144.
Chapple CR, Rechberger T, Al-Shukri S, Meffan P, Everaert K, Huang M, Ridder A; YM-905 Study Group (2004): Randomized, double-blind placebo- and tolterodinecontrolled trial of the once-daily antimuscarinic agent solifenacin in patients with symptomatic overactive bladder. Brit J Urol Int. 93: 303–310.
Chapple CR, Montorsi F, Tammela TL, Wirth M, Koldewijn E, Fernández Fernández E; European Silodosin Study Group (2011): Silodosin therapy for lower urinary tract symptoms in men with suspected benign prostatic hyperplasia: results of an international, randomized, double-blind, placebo- and active-controlled clinical trial performed in Europe. Eur Urol. 59: 342–352.
Choo MS, Lee JZ, Lee JB, Kim YH, Jung HC, Lee KS, Kim JC, Seo JT, Paick JS, Kim HJ, Na YG, Lee JG (2008): Efficacy and safety of solifenacin succinate in Korean patients with overactive bladder: a randomised, prospective, double-blind, multicentre study. Int J Clin Pract. 62: 1675–1683.
Djavan B, Marberger M (1999). A meta-analysis on the efficacy and tolerability of alpha1- adrenoceptor antagonists in patients with lower urinary tract symptoms suggestive of benign prostatic obstruction. Eur Urol 36: 1–13.
European Medicines Agency (EMEA) (2004): Ausschuss für Humanarzneimittel. Europäischer Bewertungsbericht (EPAR) Emselex. Im Internet: www.emea.eu.int/humandocs/HUMANS/EPAR/emselex/emselex.htm
Flanigan RC, Reda DJ, Wasson JH, Anderson RJ, Abdellatif M, Bruskewitz RC (1998): 5-year outcome of surgical resection and watchful waiting for men with moderately symptomatic benign prostatic hyperplasia: a Department of Veterans Affairs cooperative study. J Urol 160: 12–16.
Grünewald V (2005): Pharmakologische Therapie von neurogenen Harnblasenfunktionsstörungen. In Truß MC et al: Pharmakotherapie in der Urologie. Springer Medizin Verlag Heidelberg, S.383–311.
Haab F, Stewart L, Dwyer P (2004): Darifenacin, an M3 selective receptor antagonist, is an effective and well-tolerated once-daily treatment for overactive bladder. Eur Urol 45: 420–429.
Harvey M-A, Baker K, Wells GA (2003): Tolterodine versus oxybutynin in the treatment of urge urinary incontinence: A meta-analysis. Am J Obstet Gynecol 185: 56–61.
Hay-Smith J, Herbison P, Ellis G, Morris A (2005): Which anticholinergic drug for overactive bladder symptoms in adults. Cochrane Database Syst Rev. 2005; 3: CD005429
Kelleher CJ, Cardozo L, Chapple CR, Haab F, Ridder AM (2005): Improved quality of life in patients with overactive bladder symptoms treated with solifenacin. BJU Int. 95: 81–85.
Kirby RS, Roehrborn C, Boyle P, Bartsch G, Jardin A, Cary MM, Sweeney M, Grossman EB and the Prospective European Doxazosin and Combination Therapy Study Investigators (2003): Efficacy and tolerability of doxazosin and finasteride, alone or in combination, in treatment of symptomatic benign prostatic hyperplasia: the Prospective European Doxazosin and Combination Therapy (PRE-DICT) trial. Urology 61: 119–126.
McConnell JD, Roehrborn CG, Bautista OM, Andriole GL Jr, Dixon CM, Kusek JW, Lepor H, McVary KT, Nyberg LM Jr, Clarke HS, Crawford ED, Diokno A, Foley JP, Foster HE, Jacobs SC, Kaplan SA, Kreder KJ, Lieber MM, Lucia MS, Miller GJ, Menon M, Milam DF, Ramsdell JW, Schenkman NS, Slawin KM, Smith JA; Medical Therapy of Prostatic Symptoms (MTOPS) Research Group (2003): The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia. N Engl J Med 349: 2387–2398.
Milani S, Djavan B (2005): Lower urinary tract symptoms suggestive of benign prostatic hyperplasia: latest update on alpha-adrenoceptor antagonists. BJU Int 95 (Suppl 4): 29–36.
Millard RJ, Moore K, Rencken R, Yalcin I, Bump RC; Duloxetine UI Study Group (2004): Duloxetine vs placebo in the treatment of stress urinary incontinence: a four-continent randomized clinical trial. Brit J Urol Int 93: 311–318.
Nabi G, Cody JD, Ellis G, Herbison P, Hay-Smith J. Anticholinergic drugs versus placebo for overactive bladder syndrome in adults. Cochrane Database Syst Rev. 2006; 4: CD003781.
Nickel JC, Gilling P, Tammela TL, Morrill B, Wilson TH, Rittmaster RS (2011): Comparison of dutasteride and finasteride for treating benign prostatic hyperplasia: the Enlarged Prostate International Comparator Study (EPICS). BJU Int 108: 388–394.
Roehrborn CG, Siami P, Barkin J, Damião R, Major-Walker K, Nandy I, Morrill BB, Gagnier RP, Montorsi F; CombAT Study Group (2010): The effects of combination therapy with dutasteride and tamsulosin on clinical outcomes in men with symptomatic benign prostatic hyperplasia: 4-year results from the CombAT study. Eur Urol 57: 123–131.
Roehrborn CG, Barkin J, Siami P, Tubaro A, Wilson TH, Morrill BB, Gagnier RP (2011). Clinical outcomes after combined therapy with dutasteride plus tamsulosin or either monotherapy in men with benign prostatic hyperplasia (BPH) by baseline characteristics: 4-year results from the randomized, double-blind Combination of Avodart and Tamsulosin (CombAT) trial. BJU Int 107: 946–954.
Thüroff JW, Chartier-Kastler E, Corcus J, Humke J, Jonas U, Palmtag H, Tanagho EA (1998): Medical treatment and medical side effects in urinary incontinence in the elderly. World J Urol 16 (suppl): S48–S61.
Tsujii T (2000): Comparison of prazosin, terazosin and tamsulosin in the treatment of symptomatic benign prostatic hyperplasia: a short-term open, randomized multicenter study. Int J Urol 7: 199–205.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2013 Springer-Verlag Berlin, Heidelberg
About this chapter
Cite this chapter
Mühlbauer, B., Osswald, H. (2013). Urologika. In: Schwabe, U., Paffrath, D. (eds) Arzneiverordnungs-Report 2013. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-37124-0_43
Download citation
DOI: https://doi.org/10.1007/978-3-642-37124-0_43
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-642-37123-3
Online ISBN: 978-3-642-37124-0
eBook Packages: Medicine (German Language)